Otsuka reports phase 3 Voyxact data in IgA nephropathy

CURRENT FULL VERSION: Otsuka Pharmaceutical is reporting phase 3 VISIONARY trial data that strengthen the case for Voyxact, its APRIL-targeting therapy for primary IgA nephropathy. The headline result is familiar but still important: in the prespecified interim analysis, Voyxact reduced proteinuria by roughly half at nine months compared with placebo in adults already receiving supportive care, a result that helped underpin the drug’s FDA accelerated approval in November 2025. Otsuka’s nephrology update also arrives as the company is making a separate strategic push elsewhere in its pipeline: through Otsuka America, it has agreed to acquire Transcend Therapeutics for about $1.225 billion, including $700 million upfront and up to about $525 million tied to sales milestones, with closing expected in Q2 2026. (otsuka.co.jp)

The backdrop is a quickly changing IgA nephropathy treatment landscape. For years, care centered on supportive therapy such as maximally tolerated ACE inhibitors or ARBs, with SGLT2 inhibitors increasingly layered in when appropriate. More recently, regulators have begun clearing targeted agents on the basis of proteinuria reduction, while requiring longer-term confirmation that these drugs preserve kidney function. Voyxact entered that environment as an anti-APRIL monoclonal antibody designed to reduce pathogenic galactose-deficient IgA1 and downstream immune complex formation, aiming at a core disease mechanism rather than only the consequences of kidney injury. At the same time, Otsuka is signaling a broader appetite for specialty innovation: the planned Transcend deal would add TSND-201, or methylone, a phase 3 PTSD candidate with US patient recruitment underway, and also bring in earlier prodrug programs intended to improve efficacy, safety, and tolerability. (otsuka.co.jp)

According to Otsuka, VISIONARY is a multicenter, randomized, double-blind, placebo-controlled trial and the largest IgA nephropathy study to date, enrolling about 510 adults with biopsy-confirmed disease and eGFR of at least 30 mL/min/1.73 m² on background standard-of-care therapy. Participants received Voyxact 400 mg subcutaneously every four weeks or placebo. The primary endpoint was change in 24-hour urine protein-to-creatinine ratio at nine months, and the key secondary endpoint is annualized eGFR slope over about 24 months. In the interim dataset used for regulatory review, FDA said patients on Voyxact had a 50% reduction in proteinuria at nine months, while placebo patients had a 2% increase. (otsuka.co.jp)

Those results were strong enough to support FDA accelerated approval, but the label also makes clear the remaining questions. Voyxact is approved to reduce proteinuria in adults with primary IgA nephropathy at risk for progression, not yet on the basis of confirmed long-term renal benefit. FDA notes that the drug suppresses the immune system and may raise infection risk, and live vaccines are not recommended shortly before or during treatment. That means uptake will likely depend not only on efficacy, but also on how clinicians weigh monitoring burden, route of administration, safety, and sequencing against other newly available IgA nephropathy options. (fda.gov)

Expert commentary around the program has been broadly positive. Otsuka cited Dana Rizk, MD, a VISIONARY investigator at the University of Alabama at Birmingham, saying the 51.2% placebo-adjusted proteinuria reduction affirmed belief in sibeprenlimab’s efficacy and that the emerging safety profile was reassuring. External coverage has echoed that view, and HCPLive reported nephrologist Jonathan Barratt, MBChB, PhD, describing the earlier data as promising while emphasizing that the field still needs the 2026 kidney function results. That caution matters, because proteinuria is an accepted surrogate in IgA nephropathy, but durable preservation of eGFR is the outcome that will shape long-term positioning in guidelines and practice. (otsuka.co.jp)

The Transcend acquisition does not change the Voyxact story directly, but it does add context around Otsuka’s capital allocation and growth strategy. PharmaShots reported that Otsuka is using the deal to expand its portfolio in psychiatric and neurological indications, with TSND-201 advancing toward phase 3 for PTSD and nonclinical work ongoing on a selected prodrug candidate ahead of an FDA IND filing. In other words, while Voyxact highlights Otsuka’s push in targeted renal immunology, the Transcend transaction suggests the company is simultaneously building depth in neuropsychiatry through both late-stage and earlier pipeline assets.

Why it matters: For veterinary professionals, this isn’t a practice-changing animal health story, but it is a useful signal from comparative and translational medicine. Immune-mediated kidney disease remains an area where mechanism-specific therapies are drawing more attention, and Voyxact’s progress shows how developers are trying to move upstream in disease biology. It also highlights a broader regulatory pattern: targeted renal therapies may reach market on surrogate endpoints first, then face a second, more consequential test when kidney function data mature. The added corporate context matters too. Otsuka’s planned Transcend buyout shows how large drugmakers are balancing focused bets like APRIL inhibition in nephrology with expansion into other specialty areas, a reminder that platform building and portfolio diversification often shape how aggressively companies can support follow-on studies, commercialization, and lifecycle development. (fda.gov)

What to watch: The key event now is the confirmatory VISIONARY kidney outcomes readout, especially annualized eGFR slope over about 24 months. Otsuka said in mid-2025 that the trial was expected to complete in early 2026, although ClinicalTrials.gov lists a later study completion date, suggesting follow-up and final data handling may extend beyond the first topline disclosures. In practical terms, the next meaningful inflection point is whether Voyxact can show that its proteinuria effect translates into slower kidney function decline, which would strengthen its competitive position and support the case for full approval. In parallel, the Transcend acquisition is expected to close in Q2 2026 and would give Otsuka a new late-stage PTSD program plus earlier prodrug candidates designed to improve methylone’s efficacy, safety, and tolerability.